Completed PHASE3 INTERVENTIONAL 2-arm NCT00753688

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy (PALETTE)

A Randomized Double Blind Phase III Trial of Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

Sponsor: GlaxoSmithKline

Conditions Sarcoma, Soft Tissue

Interventions PAZOPANIB Placebo

Updated 7 times since 2017 Last updated: Aug 15, 2013 Started: Oct 31, 2008 Primary completion: Nov 30, 2010 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Sarcoma, Soft Tissue, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Amsterdam, Netherlands , Bad Saarow, Germany , Birmingham, United States , Bordeaux, France , Boston, United States , Box Hill, Australia , Brussels, Belgium , Candiolo (TO), Italy , Chiba, Japan and 63 more locations